Insecticides India Ltd: CRISIL Affirms A+/Stable Rating

CHEMICALS
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Insecticides India Ltd: CRISIL Affirms A+/Stable Rating
Overview

Insecticides (India) Ltd's credit strength remains solid, with CRISIL Ratings reaffirming its long-term rating at CRISIL A+/Stable and short-term rating at CRISIL A1. This affirmation signals ongoing financial stability for the agrochemical firm, as investors watch its growth and margin outlook.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Insecticides India Ltd: CRISIL Affirms A+/Stable Rating

Insecticides (India) Ltd's credit strength remains solid, with CRISIL Ratings reaffirming its long-term rating at CRISIL A+/Stable and short-term rating at CRISIL A1. This affirmation signals ongoing financial stability for the agrochemical firm, as investors watch its growth and margin outlook.

Key Rating Details Confirmed

Insecticides (India) Ltd announced on April 16, 2026, that CRISIL Ratings has reviewed its credit facilities. Both long-term and short-term loan ratings were affirmed and remain unchanged: CRISIL A+/Stable for long-term and CRISIL A1 for short-term. This confirms no shift in the company's assessed creditworthiness.

Why the Stable Outlook Matters

A stable credit rating from CRISIL suggests lower risk for lenders and investors. It signals the company's strong capacity to meet financial obligations, which can ease access to capital and potentially improve borrowing terms.

Past Performance and Upgrade Context

Insecticides (India) Ltd's credit profile has shown positive momentum. On June 17, 2025, CRISIL upgraded its long-term rating to CRISIL A+/Stable from CRISIL A/Stable, citing improved business risk and financial health. This upgrade followed revenue compound annual growth rate (CAGR) of about 10% through FY2025, with an estimated FY2025 revenue of ₹2,000 crore and projected FY2026 revenue growth of 8-10%. The company’s operating margin improved to around 11% in FY2025, alongside net cash accrual of ₹160 crore. Before that, in March 2024, CRISIL reaffirmed its CRISIL A/Stable/CRISIL A1 ratings, acknowledging the company's established market presence and strong financials.

Investor Confidence and Future Funding

For shareholders, reaffirming strong credit ratings typically boosts confidence. It signals financial discipline and stability, positive signs for investment. The company may find it easier to secure funding for future growth plans.

Industry Challenges and Mitigation

The agrochemical industry faces inherent risks, including potential government bans on certain pesticides and adverse weather affecting demand. The company uses prudent procurement and a diverse product portfolio to help manage these industry challenges.

Competitive Landscape

Insecticides (India) Ltd's CRISIL A+/Stable rating is strong within the sector. Competitor India Pesticides Limited holds CARE A+; Stable/CARE A1+ ratings, while Crop Chemicals India Ltd (CCIL) has a CRISIL BBB/Stable rating. Major players like UPL Ltd and Rallis India Ltd also have varying credit assessments.

Financial Snapshot

As of March 2025, Insecticides (India) Ltd's total debt was approximately ₹100 crore. Projected revenue for FY2026 is expected to grow between 8-10%, with operating margins estimated around 11% for FY2025.

What to Watch Next

Investors will monitor the company's ability to sustain revenue growth and operating margins. Key triggers will include future product launches and expansion into new geographies. The company's strategy for managing working capital and debt levels will also be crucial.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.